BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells

BACKGROUND: Although pazopanib treatment has become the standard chemotherapy in salvage setting for metastatic sarcoma patients, most patients progress after pazopanib treatment in 4 to 6 months. After failure to pazopanib, patients have limited options for treatment. Therefore, subsequent therapy...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Transl Oncol
Autors principals: Kim, Hee Kyung, Kim, Sun Young, Lee, Su Jin, Kang, Mihyeon, Kim, Seung Tae, Jang, Jiryeon, Rath, Oliver, Schueler, Julia, Lee, Dong Woo, Park, Woong Yang, Kim, Sung Joo, Park, Se Hoon, Lee, Jeeyun
Format: Artigo
Idioma:Inglês
Publicat: Neoplasia Press 2016
Matèries:
Original article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4907899/
https://ncbi.nlm.nih.gov/pubmed/27267837
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2016.03.008
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars